Synthesis of macrocyclic nucleoside antibacterials and their interactions with MraY

Dual-stabilized selenium nanoparticles with chitosan and SS31 peptide: Resolving instability for enhancing ROS elimination, suppressing inflammation, and combating bacterial infections

Selenium nanoparticles (SeNPs) hold significant promise for managing inflammatory microenvironments due to their anti-inflammatory, antioxidant, and tissue-regenerative properties. However, their poor stability limits practical applications. To address this, we developed a novel nanocomposite by co-stabilizing SeNPs with chitosan and the mitochondria-targeting peptide SS31 (CS/SS31-SeNPs) via a redox synthesis method. The optimized CS/SS31-SeNPs exhibited a uniform spherical structure (82 nm diameter, +48 mV zeta potential) and exceptional stability (no aggregation over 90 days), as confirmed by dynamic light scattering, TEM, EDX, XPS and TGA analyses. The nanocomposites demonstrated enhanced reactive oxygen species (ROS) scavenging efficiency in vitro and in vivo. In a copper sulfate-induced zebrafish inflammation model, CS/SS31-SeNPs pretreatment reduced neutrophil and macrophage recruitment by 38.07 % and 43.56 %, respectively, outperforming bare SeNPs. Furthermore, CS/SS31-SeNPs exhibited superior antibacterial activity against Staphylococcus aureus, achieving near-complete growth inhibition at 64 μM. Mechanistic studies revealed that the antibacterial action stems from targeting the conserved MraY enzyme in peptidoglycan synthesis. Molecular docking indicated stable binding (-15.6 kcal/mol) of CS/SS31-SeNPs to MraY's uracil pocket and adjacent sites-a mechanism distinct from conventional antibiotics, suggesting broad-spectrum potential. By synergistically integrating chitosan's antibacterial properties with SS31's mitochondrial targeting, CS/SS31-SeNPs overcome SeNPs instability while amplifying their therapeutic efficacy. This multifunctional platform offers a promising strategy for treating oral-craniofacial inflammatory and infectious diseases, with implications for antibiotic resistance mitigation.

Advances in Coordination Chemistry of Schiff Base Complexes: A Journey from Nanoarchitectonic Design to Biomedical Applications

Since the discovery of Schiff bases over one and a half centuries ago, there has been tremendous research activity in the design of various Schiff bases and examination of their diverse structures and versatile applications. This family of compounds has continued to captivate many research groups due to the simplicity of their synthesis through the condensation of amines with carbonyl compounds. While conventional synthesis has been the most widely used, green synthetic methodologies have been also explored for this reaction, including sonication, microwave-assisted, natural acid-catalyzed and mechanochemical syntheses as well as utilizing ionic liquid solvents or deep eutectic solvents. Schiff bases have been utilized as excellent ligands for coordination to transition metals and late transition metals (lanthanides and actinides). These Schiff base compounds can be mono-, di-, or polydentate ligands. The aim of this review is to examine the biological applications of Schiff base complexes over the past decade with particular focus on their antimicrobial, antiviral, anticancer, antidiabetic, and anti-inflammatory activity. Schiff base complexes have been found effective in combating bacterial and fungal infections with numerous examples in the literature. The review addressed this area by focusing on the very recent examples while using tables to summarize the vast breadth of research according to the metallic moieties. Viruses have continued to be a target of many researchers in light of their continuous mutations and impact on human health, and therefore some examples of Schiff base complexes with antiviral activity are described. Cancer continues to be among the leading causes of death worldwide. In this article, the use of Schiff base complexes for, and the mechanisms associated with, their anticancer activity are highlighted. The production of reactive oxygen species (ROS) or intercalation with DNA base pairs leading to cell cycle arrest were the main mechanisms described. While there have been some efforts made to use Schiff base complexes as antidiabetic or anti-inflammatory agents, there are limited examples when compared with antimicrobial and anticancer studies. The conclusion of this review highlights the emerging areas of research and future perspectives with an emphasis on the potential uses of Schiff bases in the treatment of infectious and noninfectious diseases.

1,2,4-Triazole-based first-in-class non-nucleoside inhibitors of bacterial enzyme MraY

MraY, a bacterial enzyme crucial for the synthesis of peptidoglycans, represents a promising yet underexplored target for the development of effective antibacterial agents. Nature has provided several classes of nucleoside inhibitors of MraY and scientists have modified these structures further to obtain natural product-like inhibitors of MraY. The natural products and their synthetic analogs suffer from non-optimal in vivo efficacy, and the synthetic complexity of the structures renders the synthesis and structure-activity relationship (SAR) studies of these molecules particularly challenging. In this study, we present our findings on the discovery of first-in-class 1,2,4-triazole-based MraY inhibitors that are not nucleoside-derived. A series of 1,2,4-triazole analogous were identified by a structure-activity-relationship (SAR) study using a structure-based drug design strategy. Compound 1 , with an IC 50 of 171 µM against MraY from Staphylococcus aureus (MraY SA ), was optimized to compound 12a , exhibiting an IC 50 of 25 µM. Molecular docking studies against MraY SA provided insights into these compounds' binding interactions and activity. Furthermore, screening against the ESKAPE bacterial panel was also conducted, through which we discovered compounds demonstrating broad-spectrum antibacterial activity against E. faecium , methicillin-resistant S. aureus (MRSA), vancomycin-resistant Enterococci (VRE) strains and Mycobacterium tuberculosis . The novel, first-in-class non-nucleoside inhibitors of MraY highlighted in this work provide a strong proof-of-concept of how to leverage structural information of the protein to develop future antibacterial agents targeting MraY.

Abstract Figure

Identifying Opportunity Targets in Gram-Negative Pathogens for Infectious Disease Mitigation

Antimicrobial drug resistance (AMR) is a pressing global human health challenge. Humans face one of their grandest challenges as climate change expands the habitat of vectors that bear human pathogens, incidences of nosocomial infections rise, and new antibiotics discovery lags. AMR is a multifaceted problem that requires a multidisciplinary and an "all-hands-on-deck" approach. As chemical microbiologists, we are well positioned to understand the complexities of AMR while seeing opportunities for tackling the challenge. In this Outlook, we focus on vulnerabilities of human pathogens and posit that they represent "opportunity targets" for which few modulatory ligands exist. We center our attention on proteins in Gram-negative organisms, which are recalcitrant to many antibiotics because of their external membrane barrier. Our hope is to highlight such targets and explore their potential as "druggable" proteins for infectious disease mitigation. We posit that success in this endeavor will introduce new classes of antibiotics that might alleviate some of the current pressing AMR concerns.

Development of a natural product optimization strategy for inhibitors against MraY, a promising antibacterial target

MraY (phospho-N-acetylmuramoyl-pentapeptide-transferase) inhibitory natural products are attractive molecules as candidates for a new class of antibacterial agents to combat antimicrobial-resistant bacteria. Structural optimization of these natural products is required to improve their drug-like properties for therapeutic use. However, chemical modifications of these natural products are painstaking tasks due to complex synthetic processes, which is a bottleneck in advancing natural products to the clinic. Here, we develop a strategy for a comprehensive in situ evaluation of the build-up library, which enables us to streamline the preparation of the analogue library and directly assess its biological activities. We apply this approach to a series of MraY inhibitory natural products. Through construction and evaluation of the 686-compound library, we identify promising analogues that exhibit potent and broad-spectrum antibacterial activity against highly drug-resistant strains in vitro as well as in vivo in an acute thigh infection model. Structures of the MraY-analogue complexes reveal distinct interaction patterns, suggesting that these analogues represent MraY inhibitors with unique binding modes. We further demonstrate the generality of our strategy by applying it to tubulin-binding natural products to modulate their tubulin polymerization activities.

Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections

Advances in areas that include genomics, systems biology, protein structure determination and artificial intelligence provide new opportunities for target-based antibacterial drug discovery. The selection of a 'good' new target for direct-acting antibacterial compounds is the first decision, for which multiple criteria must be explored, integrated and re-evaluated as drug discovery programmes progress. Criteria include essentiality of the target for bacterial survival, its conservation across different strains of the same species, bacterial species and growth conditions (which determines the spectrum of activity of a potential antibiotic) and the level of homology with human genes (which influences the potential for selective inhibition). Additionally, a bacterial target should have the potential to bind to drug-like molecules, and its subcellular location will govern the need for inhibitors to penetrate one or two bacterial membranes, which is a key challenge in targeting Gram-negative bacteria. The risk of the emergence of target-based drug resistance for drugs with single targets also requires consideration. This Review describes promising but as-yet-unrealized targets for antibacterial drugs against Gram-negative bacteria and examples of cognate inhibitors, and highlights lessons learned from past drug discovery programmes.

A review of current antibiotic resistance and promising antibiotics with novel modes of action to combat antibiotic resistance

The emergence and transmission of antibiotic resistance is a global public health crisis with significant burden on healthcare systems, resulting in high mortality and economic costs. In 2019, almost five million deaths were associated with drug-resistant infections, and if left unchecked, the global economy could lose $100 trillion by 2050. To effectively combat this crisis, it is essential for all countries to understand the current situation of antibiotic resistance. In this review, we examine the current driving factors leading to the crisis, impact of critical superbugs in three regions, and identify novel mechanisms of antibiotic resistance. It is crucial to monitor the phenotypic characteristics of drug-resistant pathogens and describe the mechanisms involved in preventing the emergence of cross-resistance to novel antimicrobials. Additionally, maintaining an active pipeline of new antibiotics is essential for fighting against diverse antibiotic-resistant pathogens. Developing antibacterial agents with novel mechanisms of action is a promising way to combat increasing antibiotic-resistant pathogens.

Structure-Based Insight on the Mechanism of N-Glycosylation Inhibition by Tunicamycin

N-glycosylation, a common post-translational modification, is widely acknowledged to have a significant effect on protein stability and folding. N-glycosylation is a complex process that occurs in the endoplasmic reticulum (ER) and requires the participation of multiple enzymes. GlcNAc-1-P-transferase (GPT) is essential for initiating N-glycosylation in the ER. Tunicamycin is a natural product that inhibits N-glycosylation and produces ER stress, and thus it is utilized in research. The molecular mechanism by which GPT triggers N-glycosylation is discussed in this review based on the GPT structure. Based on the structure of the GPT-tunicamycin complex, we also discuss how tunicamycin reduces GPT activity, which prevents N-glycosylation. This review will be highly useful for understanding the role of GPT in the N-glycosylation of proteins, as well as presents a potential for considering tunicamycin as an antibiotic treatment.

An Update Review of Approaches to Multiple Action-Based Antibacterials

Many approaches are being pursued to address the major global health challenge posed by the increasing resistance of pathogenic bacteria to antibacterial agents. One of the promising approaches being investigated includes the design and development of multiple action-based small-molecule antibacterials. Aspects of this broad area have been reviewed previously, and recent developments are addressed in this update review covering the literature mainly over the past three years. Considerations encompassing drug combinations, single-molecule hybrids and prodrugs are summarised in regard to the intentional design and development of multiple-action agents with a focus on potential triple or greater activities in bacteria. The hope for such single agents or combinations of single agents is that resistance development will be significantly hindered, and they may be useful in tackling bacterial disease caused by both resistant and non-resistant bacteria.

Computational Approaches to Enzyme Inhibition by Marine Natural Products in the Search for New Drugs

The exploration of biologically relevant chemical space for the discovery of small bioactive molecules present in marine organisms has led not only to important advances in certain therapeutic areas, but also to a better understanding of many life processes. The still largely untapped reservoir of countless metabolites that play biological roles in marine invertebrates and microorganisms opens new avenues and poses new challenges for research. Computational technologies provide the means to (i) organize chemical and biological information in easily searchable and hyperlinked databases and knowledgebases; (ii) carry out cheminformatic analyses on natural products; (iii) mine microbial genomes for known and cryptic biosynthetic pathways; (iv) explore global networks that connect active compounds to their targets (often including enzymes); (v) solve structures of ligands, targets, and their respective complexes using X-ray crystallography and NMR techniques, thus enabling virtual screening and structure-based drug design; and (vi) build molecular models to simulate ligand binding and understand mechanisms of action in atomic detail. Marine natural products are viewed today not only as potential drugs, but also as an invaluable source of chemical inspiration for the development of novel chemotypes to be used in chemical biology and medicinal chemistry research.

Antibacterial Nanomaterials: Mechanisms, Impacts on Antimicrobial Resistance and Design Principles

Antimicrobial resistance (AMR) is one of the biggest threats to the environment and health. AMR rapidly invalidates conventional antibiotics, and antimicrobial nanomaterials have been increasingly explored as alternatives. Interestingly, several antimicrobial nanomaterials show AMR-independent antimicrobial effects without detectable new resistance and have therefore been suggested to prevent AMR evolution. In contrast, some are found to trigger the evolution of AMR. Given these seemingly conflicting findings, a timely discussion of the two faces of antimicrobial nanomaterials is urgently needed. This review systematically compares the killing mechanisms and structure-activity relationships of antibiotics and antimicrobial nanomaterials. We then focus on nano-microbe interactions to elucidate the impacts of molecular initiating events on AMR evolution. Finally, we provide an outlook on future antimicrobial nanomaterials and propose design principles for the prevention of AMR evolution.